Filtered By:
Cancer: Adenocarcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 24262 results found since Jan 2013.
Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery
CONCLUSIONS: There were no significant differences in survival or SAEs based on the networks of systemic therapy delivery. This suggests that patients undergoing CRS at a high-volume center may safely receive systemic therapy at outside-network facilities with comparable outcomes.PMID:37737968 | DOI:10.1245/s10434-023-14318-1
Source: Ann Oncol - September 22, 2023 Category: Cancer & Oncology Authors: Mason Vierra Varun V Bansal Ryan B Morgan Hunter D D Witmer Biren Reddy Ankit Dhiman Frederick A Godley Cecilia T Ong Erika Belmont Blas é Polite Ardaman Shergill Kiran K Turaga Oliver S Eng Source Type: research
Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma
Oncologist. 2023 Sep 20:oyad263. doi: 10.1093/oncolo/oyad263. Online ahead of print.ABSTRACTAppendiceal cancer is a rare, orphan disease with no therapies currently approved by the FDA for its treatment. Given the limited data regarding drug efficacy, these tumors have historically been treated with chemotherapy designed for colon cancer. However, an overwhelming body of molecular data has demonstrated that appendiceal adenocarcinoma is a distinct entity with key molecular differences from colon cancer, notably rare APC mutation. Recognizing that APC loss-of-function is thought to contribute to taxane resistance and that t...
Source: The Oncologist - September 22, 2023 Category: Cancer & Oncology Authors: Julia Dansby Aditya More Mohammad Zeineddine Abdelrahman Yousef Alisha Bent Farshid Dayyani Robert Wolff Michael Overman John Paul Shen Source Type: research
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
DISCUSSION: This trial will help define the best neoadjuvant treatment sequence for borderline resectable PDAC and aims to evaluate if a total neoadjuvant treatment integrating iHD-SBRT improves the patients' oncological outcomes.TRIAL REGISTRATION: The study was registered at ClinicalTrails.gov (NCT05083247) on October 19th, 2021, and in the Clinical Trials Information System (CTIS) EU CT database (2022-501181-22-01) on July 2022.PMID:37735634 | DOI:10.1186/s12885-023-11327-x
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Christelle Bouchart Julie Navez Ivan Borbath Karen Geboes Timon Vandamme Jean Closset Luigi Moretti Pieter Demetter Marianne Paesmans Jean-Luc Van Laethem Source Type: research
Epigenetic reprogramming of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung adenocarcinoma
Nucleic Acids Res. 2023 Sep 22:gkad734. doi: 10.1093/nar/gkad734. Online ahead of print.ABSTRACTEnhancer reprogramming has been proposed as a key source of transcriptional dysregulation during tumorigenesis, but the molecular mechanisms underlying this process remain unclear. Here, we identify an enhancer cluster required for normal development that is aberrantly activated in breast and lung adenocarcinoma. Deletion of the SRR124-134 cluster disrupts expression of the SOX2 oncogene, dysregulates genome-wide transcription and chromatin accessibility and reduces the ability of cancer cells to form colonies in vitro. Analysis...
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Luis E Abatti Patricia Lado-Fern ández Linh Huynh Manuel Collado Michael M Hoffman Jennifer A Mitchell Source Type: research
Fructose-induced mTORC1 Activation Promotes Pancreatic Cancer Progression through Inhibition of Autophagy
In this study, we investigated the functional association between fructose utilization and pancreatic ductal adenocarcinoma (PDAC) progression. Fructose could be taken up and metabolized by PDAC cells and provided an adaptive survival mechanism for PDAC cells under glucose deficient conditions. GLUT5-mediated fructose metabolism maintained the survival, proliferation, and invasion capacities of PDAC cells in vivo and in vitro. Fructose metabolism not only provided ATP and biomass to PDAC cells but also conferred metabolic plasticity to the cells, making them more adaptable to the tumor microenvironment. Mechanistically, fr...
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Yanfen Cui Jianfei Tian Zhaosong Wang Hui Guo He Zhang Zhiyong Wang Hui Liu Weijie Song Liming Liu Ruinan Tian Xiaoyan Zuo Sixin Ren Ruifang Niu Fei Zhang Source Type: research
Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T cell Immunity in Gastric Cancer Peritoneal Metastases
Cancer Res. 2023 Sep 22. doi: 10.1158/0008-5472.CAN-23-0783. Online ahead of print.ABSTRACTThe peritoneal cavity is a common site of gastric adenocarcinoma (GAC) metastasis. Peritoneal carcinomatosis (PC) is resistant to current therapies and confer poor prognosis, highlighting the need to identify new therapeutic targets. CD47 conveys a "don't eat me" signal to myeloid cells upon binding its receptor SIRPα, which helps tumor cells circumvent macrophage phagocytosis and evade innate immune responses. Previous studies demonstrated that the blockade of CD47 alone results in limited clinical benefits, suggesting that other t...
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Yibo Fan Shumei Song Yuan Li Shilpa S Dhar Jiankang Jin Katsuhiro Yoshimura Xiaodan Yao Ruiping Wang Ailing W Scott Melissa Pool Pizzi JingJing Wu Lang Ma George A Calin Samir Hanash Linghua Wang Michael Curran Jaffer A Ajani Source Type: research
A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients
CONCLUSION: FBP1, SBK1, and AURKA are prognostic risk factors, and the risk model and nomogram of FBP1, SBK1 and AURKA are associated with dismal prognosis and immune cell infiltration, and have huge prospects for application in evaluating the prognosis in LUAD.PMID:37737707 | DOI:10.18632/aging.205040
Source: Aging - September 22, 2023 Category: Biomedical Science Authors: Qiang Guo Kai Li Ni Jiang Rui Zhou Xin-Rui Rao Chuang-Yan Wu Source Type: research
CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers
CONCLUSION: Our results suggested that CYFIP2 may serve as a prognostic cancer biomarker for determining prognosis and might be a promising therapeutic strategy for tumor immunotherapy.PMID:37735711 | DOI:10.1186/s40001-023-01366-2
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Qiliang Peng Bixin Ren Kedao Xin Weihui Liu Md Shahin Alam Yinyin Yang Xuhao Gu Yaqun Zhu Ye Tian Source Type: research
Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma
Conclusion: Our results indicate that down-regulation of IL2 predicts poor prognosis and is associated with immune escape in LUAD, and IL2 could serve as a potential novel prognostic biomarker of LUAD.PMID:37731383 | DOI:10.1177/03946320231202748
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Yongwang Hou Baoli Xiang Zhicong Yang Jiangmin Liu Dandan Xu Lina Geng Minghua Zhan Yuhuan Xu Bin Zhang Source Type: research
Tetrahydrobiopterin from cyanide-degrading bacterium Bacillus pumilus strain SVD06 induces apoptosis in human lung adenocarcinoma cell (A549)
Biotechnol Appl Biochem. 2023 Sep 20. doi: 10.1002/bab.2509. Online ahead of print.ABSTRACTTetrahydrobiopterin (BH4) is an essential biological cofactor and a derivative of pterin which is considered potent anticancer agents. In continuation of our previous study on the identification of BH4 from cyanide-degrading Bacillus pumilus, the present study focuses on evaluating the anticancer properties of BH4 on A549, a human lung adenocarcinoma. Anticancer activity analysis shows that BH4 inhibited A549 cell growth after 24 h of incubation with 0.02 mg/mL. In acridine orange/ethidium bromide staining, BH4-treated A549 cells sho...
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Ramasamy Mahendran Sanjay Prasad Selvaraj Anand Raj Dhanapal Sabna Bhaskaran Sarasa Beutline Malgija Mathias Bency Thankappan Daniel Raja Femil Selta Palanivel Naveen Rhenghachar Poorani Navaneethan Sundhar Mamatha M Pillai Rajendran Selvakumar Chih-Yang Source Type: research
Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon diagnosed by molecular pathology: A case report and literature review
CONCLUSION: Based on pathological and genetic analysis, surgery combined with chemotherapy or chemoradiotherapy may have good therapeutic effects for collision tumor.PMID:37731579 | PMC:PMC10507543 | DOI:10.12998/wjcc.v11.i26.6289
Source: Clinical Colorectal Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Meng Jiang Xiao-Ping Yuan Source Type: research
Different mechanisms of CD200-CD200R induce diverse outcomes in cancer treatment
Math Biosci. 2023 Sep 19:109072. doi: 10.1016/j.mbs.2023.109072. Online ahead of print.ABSTRACTThe CD200 is a cell membrane protein expressed by tumor cells, and its receptor CD200 receptor (CD200R) is expressed by immune cells including macrophages and dendritic cells. The formation of CD200-CD200R inhibits the cellular functions of the targeted immune cells, so CD200 is one type of the immune checkpoint and blockade CD200-CD200R formation is a potential cancer treatment. However, the CD200 blockade has opposite treatment outcomes in different types of cancers. For instance, the CD200R deficient mice have a higher tumor l...
Source: Mathematical Biosciences - September 21, 2023 Category: Statistics Authors: Kang-Ling Liao Kenton D Watt Tom Protin Source Type: research
Kinesin Superfamily Member 18B (KIF18B) Promotes Cell Proliferation in Colon Adenocarcinoma Retraction
Cancer Manag Res. 2023 Sep 15;15:1011-1012. doi: 10.2147/CMAR.S440061. eCollection 2023.ABSTRACT[This retracts the article DOI: 10.2147/CMAR.S261894.].PMID:37731840 | PMC:PMC10508229 | DOI:10.2147/CMAR.S440061
Source: Cell Research - September 21, 2023 Category: Cytology Source Type: research
PD-1 blockade induces reactivation of non-productive T cell responses characterized by NF-kB signaling in patients with pancreatic cancer
CONCLUSIONS: Cytotoxic T cells in the blood of PDAC patients remain sensitive to reinvigoration by PD-1 blockade and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti-PD-1 reinvigoration and marks these T cells as non-productive contributors to anti-tumor immunity.PMID:37733830 | DOI:10.1158/1078-0432.CCR-23-1444
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Lestat R Ali Patrick J Lenehan Victoire Cardot-Ruffino Andressa Dias Costa Matthew H G Katz Todd W Bauer Jonathan A Nowak Brian M Wolpin Thomas A Abrams Anuj Patel Thomas E Clancy Jiping Wang Joseph D Mancias Matthew J Reilley Chee-Chee H Stucky Tanios S Source Type: research
